Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences Inc (FBRX) is a clinical-stage biopharmaceutical company developing FB-102, a novel therapeutic candidate targeting autoimmune conditions including graft-versus-host disease, vitiligo, and alopecia areata. This dedicated news hub provides real-time updates on preclinical advancements, regulatory milestones, and strategic initiatives shaping the company's research trajectory.
Access authoritative reports on key developments including trial design updates, intellectual property filings, and partnership announcements. Our curated news collection serves investors and researchers seeking to track FBRX's progress in immunomodulation therapies without promotional bias.
Content highlights include:
• Preclinical study results
• Research collaboration updates
• Financial performance reports
• Management commentary
Bookmark this page for streamlined access to verified FBRX developments. Regularly updated to reflect the company's evolving position in autoimmune therapeutics research.
Forte Biosciences (NASDAQ: FBRX) reported its full year 2024 results and provided a clinical update. The company highlighted significant progress in developing FB102, with the completion of a healthy volunteer study and ongoing celiac patient trial, which is progressing well with no dropouts. Topline results are expected in Q2 2025.
Financial highlights include:
- R&D expenses decreased to $21.2M from $21.9M in 2023
- G&A expenses increased to $15.4M from $10.6M in 2023
- Net loss per share improved to $(12.17) from $(24.92)
- Year-end cash position of $58.4M
The company completed a 1:25 reverse stock split in August 2024 and raised $53.0M through an over-subscribed private placement in November 2024. As of December 31, 2024, there were 6.4M shares of common stock and 5.0M prefunded warrants outstanding.
Forte Biosciences (NASDAQ: FBRX), a clinical-stage biopharmaceutical company specializing in autoimmune and autoimmune-related diseases, has announced its participation in two major investor conferences. CEO Paul Wagner, PhD will deliver presentations at:
1. The Guggenheim SMID Cap Biotech Conference on February 6th at 1:30 PM ET in New York, NY at the Lotte New York Palace
2. The TD Cowen 45th Annual Healthcare Conference on March 3rd at 10:30 AM ET in Boston, MA at the Boston Marriott Copley Place
Forte Biosciences (NASDAQ: FBRX) has announced an upcoming R&D Day scheduled for December 3, 2024 at 4:30 p.m. ET. The event will spotlight the development of FB102 across autoimmune indications, featuring prominent experts in celiac disease, vitiligo, and alopecia areata.
Distinguished speakers include Prof. Jason Tye-Din from Walter and Eliza Hall Institute, Prof. Christopher Ma from University of Calgary, and Prof. David Rosmarin from Indiana University School of Medicine. These thought leaders will share insights on their respective fields of expertise in autoimmune-related diseases.
Forte Biosciences (NASDAQ: FBRX) has secured an oversubscribed $53 million private placement from leading healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. The funding will support the clinical advancement of FB102 across autoimmune indications. The company has completed its healthy volunteer study and is currently conducting a celiac disease trial with topline results expected in Q2 2025. Forte plans to expand FB102 development into additional indications over the next 12 months.
Forte Biosciences (NASDAQ: FBRX) reported Q3 2024 results and provided updates on FB102 development. The company has begun dosing patients in a celiac disease clinical trial, with topline data expected in Q2 2025. Q3 financial results showed R&D expenses of $5.9M (down from $6.4M in Q3 2023) and G&A expenses of $2.8M (down from $3.8M). The company reported a net loss of $(4.54) per share and ended the quarter with $16.4M in cash. In August 2024, Forte implemented a 1:25 reverse split, resulting in 1.46M shares outstanding.
Forte Biosciences (NASDAQ: FBRX) announced its Q2 2024 results and provided a business update. The company reported progress with FB102, its anti-CD122 monoclonal antibody therapeutic candidate. Key highlights include:
1. Successful completion of the SAD/MAD phase 1 healthy volunteer study for FB102.
2. Initiation of a patient study in celiac disease, with data expected by Q2 2025.
3. R&D expenses decreased to $5.7 million in Q2 2024 from $7.1 million in Q2 2023.
4. General and administrative expenses increased to $7.1 million in Q2 2024 from $1.9 million in Q2 2023.
5. Net loss per share was $(0.27) for Q2 2024.
6. Cash and cash equivalents stood at $24.5 million as of June 30, 2024.
Forte Biosciences, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced the issuance of equity inducement awards under Nasdaq rules.
The Compensation Committee approved grants for 70,000 shares to new non-executive employees to incentivize their employment. Each award will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly increments over the next three years.
The awards are part of Forte's 2020 Inducement Equity Incentive Plan and have terms similar to the 2021 Equity Incentive Plan.
Forte Biosciences, a clinical-stage biopharmaceutical firm, announced its Q1 2024 results. The company reported a net loss of $7.4 million, or $0.16 per share, an improvement from $0.32 per share in the same period last year. Forte's cash reserves stood at $30.4 million by the end of the quarter. R&D expenses dropped to $4.4 million from $4.8 million YoY, while G&A expenses rose to $3.5 million from $2.1 million. The company's phase 1 trial for its drug candidate FB102 has shown a good safety profile, with completion of multiple ascending dose cohorts expected mid-year. Forte plans to start patient-based studies by year-end, aiming to address various autoimmune diseases.
FAQ
What is the current stock price of Forte Biosciences (FBRX)?
What is the market cap of Forte Biosciences (FBRX)?
